| Eye Trends | |
|
6625 Spring Stuebner Rd Ste 215, Spring, TX 77389-5356 | |
| (281) 350-2020 | |
| (832) 408-7631 |
| Full Name | Eye Trends |
|---|---|
| Type | Facility |
| Speciality | Optometrist |
| Location | 6625 Spring Stuebner Rd Ste 215, Spring, Texas |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003326893 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 3399TG (Texas) | Primary |
| Provider Name | Hamida Hemani |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1164425518 PECOS PAC ID: 9335122571 Enrollment ID: I20040609001188 |
News Archive
Two U.N. reports released on Wednesday examine the conditions faced by women around the world, the New York Times reports (MacFarquhar, 10/20). The World's Women 2010: Trends and Statistics report, which is published every five years, offers a compilation of "the latest data documenting progress for women worldwide in eight key areas: population and families, health, education, work, power and decision-making, violence against women, environment and poverty," according to a U.N. Statistics Division press release.
A team of bioengineers at Brigham and Women's Hospital is the first to report creating artificial heart tissue that closely mimics the functions of natural heart tissue through the use of human-based materials.
A groundbreaking drug that helps regulate bone development has boosted growth rates in children with achondroplasia - the most common type of dwarfism - in a global trial led by Melbourne's Murdoch Children's Research Institute.
The clinical trial was random, regulated, double-blinded and broad-based. The drug was tested on 457 patients, aged 16-45, who had been diagnosed with Type 1 diabetes a short time before joining the trial. The trial took place in around 40 medical centers in Europe, Israel and South Africa. The patients in the trial were randomly assigned to one of two groups: One received the trial drug (DiaPep277-) through a subcutaneous injection once every three months, for a period of two years, while the control group was given a placebo in the same way.
To inform policy and identify best practices in helping high school students with disabilities successfully go to college and get good jobs, Cornell's School of Industrial and Labor Relations' (ILR) Employment and Disability Institute (EDI) will partner with New York state on a five-year, $5.1 million research study.
› Verified 1 days ago
| Provider Name | Jill W Liu |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1073516324 PECOS PAC ID: 7214997790 Enrollment ID: I20041019000436 |
News Archive
Two U.N. reports released on Wednesday examine the conditions faced by women around the world, the New York Times reports (MacFarquhar, 10/20). The World's Women 2010: Trends and Statistics report, which is published every five years, offers a compilation of "the latest data documenting progress for women worldwide in eight key areas: population and families, health, education, work, power and decision-making, violence against women, environment and poverty," according to a U.N. Statistics Division press release.
A team of bioengineers at Brigham and Women's Hospital is the first to report creating artificial heart tissue that closely mimics the functions of natural heart tissue through the use of human-based materials.
A groundbreaking drug that helps regulate bone development has boosted growth rates in children with achondroplasia - the most common type of dwarfism - in a global trial led by Melbourne's Murdoch Children's Research Institute.
The clinical trial was random, regulated, double-blinded and broad-based. The drug was tested on 457 patients, aged 16-45, who had been diagnosed with Type 1 diabetes a short time before joining the trial. The trial took place in around 40 medical centers in Europe, Israel and South Africa. The patients in the trial were randomly assigned to one of two groups: One received the trial drug (DiaPep277-) through a subcutaneous injection once every three months, for a period of two years, while the control group was given a placebo in the same way.
To inform policy and identify best practices in helping high school students with disabilities successfully go to college and get good jobs, Cornell's School of Industrial and Labor Relations' (ILR) Employment and Disability Institute (EDI) will partner with New York state on a five-year, $5.1 million research study.
› Verified 1 days ago
| Provider Name | Douglas M. Inns |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1235101668 PECOS PAC ID: 4284617424 Enrollment ID: I20041123001308 |
News Archive
Two U.N. reports released on Wednesday examine the conditions faced by women around the world, the New York Times reports (MacFarquhar, 10/20). The World's Women 2010: Trends and Statistics report, which is published every five years, offers a compilation of "the latest data documenting progress for women worldwide in eight key areas: population and families, health, education, work, power and decision-making, violence against women, environment and poverty," according to a U.N. Statistics Division press release.
A team of bioengineers at Brigham and Women's Hospital is the first to report creating artificial heart tissue that closely mimics the functions of natural heart tissue through the use of human-based materials.
A groundbreaking drug that helps regulate bone development has boosted growth rates in children with achondroplasia - the most common type of dwarfism - in a global trial led by Melbourne's Murdoch Children's Research Institute.
The clinical trial was random, regulated, double-blinded and broad-based. The drug was tested on 457 patients, aged 16-45, who had been diagnosed with Type 1 diabetes a short time before joining the trial. The trial took place in around 40 medical centers in Europe, Israel and South Africa. The patients in the trial were randomly assigned to one of two groups: One received the trial drug (DiaPep277-) through a subcutaneous injection once every three months, for a period of two years, while the control group was given a placebo in the same way.
To inform policy and identify best practices in helping high school students with disabilities successfully go to college and get good jobs, Cornell's School of Industrial and Labor Relations' (ILR) Employment and Disability Institute (EDI) will partner with New York state on a five-year, $5.1 million research study.
› Verified 1 days ago
| Provider Name | Michael D Toups |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1922070192 PECOS PAC ID: 8123000916 Enrollment ID: I20041207000467 |
News Archive
Two U.N. reports released on Wednesday examine the conditions faced by women around the world, the New York Times reports (MacFarquhar, 10/20). The World's Women 2010: Trends and Statistics report, which is published every five years, offers a compilation of "the latest data documenting progress for women worldwide in eight key areas: population and families, health, education, work, power and decision-making, violence against women, environment and poverty," according to a U.N. Statistics Division press release.
A team of bioengineers at Brigham and Women's Hospital is the first to report creating artificial heart tissue that closely mimics the functions of natural heart tissue through the use of human-based materials.
A groundbreaking drug that helps regulate bone development has boosted growth rates in children with achondroplasia - the most common type of dwarfism - in a global trial led by Melbourne's Murdoch Children's Research Institute.
The clinical trial was random, regulated, double-blinded and broad-based. The drug was tested on 457 patients, aged 16-45, who had been diagnosed with Type 1 diabetes a short time before joining the trial. The trial took place in around 40 medical centers in Europe, Israel and South Africa. The patients in the trial were randomly assigned to one of two groups: One received the trial drug (DiaPep277-) through a subcutaneous injection once every three months, for a period of two years, while the control group was given a placebo in the same way.
To inform policy and identify best practices in helping high school students with disabilities successfully go to college and get good jobs, Cornell's School of Industrial and Labor Relations' (ILR) Employment and Disability Institute (EDI) will partner with New York state on a five-year, $5.1 million research study.
› Verified 1 days ago
| Provider Name | Lauren A Tom |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1710174081 PECOS PAC ID: 0042308686 Enrollment ID: I20091015000369 |
News Archive
Two U.N. reports released on Wednesday examine the conditions faced by women around the world, the New York Times reports (MacFarquhar, 10/20). The World's Women 2010: Trends and Statistics report, which is published every five years, offers a compilation of "the latest data documenting progress for women worldwide in eight key areas: population and families, health, education, work, power and decision-making, violence against women, environment and poverty," according to a U.N. Statistics Division press release.
A team of bioengineers at Brigham and Women's Hospital is the first to report creating artificial heart tissue that closely mimics the functions of natural heart tissue through the use of human-based materials.
A groundbreaking drug that helps regulate bone development has boosted growth rates in children with achondroplasia - the most common type of dwarfism - in a global trial led by Melbourne's Murdoch Children's Research Institute.
The clinical trial was random, regulated, double-blinded and broad-based. The drug was tested on 457 patients, aged 16-45, who had been diagnosed with Type 1 diabetes a short time before joining the trial. The trial took place in around 40 medical centers in Europe, Israel and South Africa. The patients in the trial were randomly assigned to one of two groups: One received the trial drug (DiaPep277-) through a subcutaneous injection once every three months, for a period of two years, while the control group was given a placebo in the same way.
To inform policy and identify best practices in helping high school students with disabilities successfully go to college and get good jobs, Cornell's School of Industrial and Labor Relations' (ILR) Employment and Disability Institute (EDI) will partner with New York state on a five-year, $5.1 million research study.
› Verified 1 days ago
| Provider Name | Michelle T Pham |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1144574419 PECOS PAC ID: 1759528359 Enrollment ID: I20130517000371 |
News Archive
Two U.N. reports released on Wednesday examine the conditions faced by women around the world, the New York Times reports (MacFarquhar, 10/20). The World's Women 2010: Trends and Statistics report, which is published every five years, offers a compilation of "the latest data documenting progress for women worldwide in eight key areas: population and families, health, education, work, power and decision-making, violence against women, environment and poverty," according to a U.N. Statistics Division press release.
A team of bioengineers at Brigham and Women's Hospital is the first to report creating artificial heart tissue that closely mimics the functions of natural heart tissue through the use of human-based materials.
A groundbreaking drug that helps regulate bone development has boosted growth rates in children with achondroplasia - the most common type of dwarfism - in a global trial led by Melbourne's Murdoch Children's Research Institute.
The clinical trial was random, regulated, double-blinded and broad-based. The drug was tested on 457 patients, aged 16-45, who had been diagnosed with Type 1 diabetes a short time before joining the trial. The trial took place in around 40 medical centers in Europe, Israel and South Africa. The patients in the trial were randomly assigned to one of two groups: One received the trial drug (DiaPep277-) through a subcutaneous injection once every three months, for a period of two years, while the control group was given a placebo in the same way.
To inform policy and identify best practices in helping high school students with disabilities successfully go to college and get good jobs, Cornell's School of Industrial and Labor Relations' (ILR) Employment and Disability Institute (EDI) will partner with New York state on a five-year, $5.1 million research study.
› Verified 1 days ago
| Provider Name | Sarah Quelly |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1467892950 PECOS PAC ID: 8022249317 Enrollment ID: I20140331000932 |
News Archive
Two U.N. reports released on Wednesday examine the conditions faced by women around the world, the New York Times reports (MacFarquhar, 10/20). The World's Women 2010: Trends and Statistics report, which is published every five years, offers a compilation of "the latest data documenting progress for women worldwide in eight key areas: population and families, health, education, work, power and decision-making, violence against women, environment and poverty," according to a U.N. Statistics Division press release.
A team of bioengineers at Brigham and Women's Hospital is the first to report creating artificial heart tissue that closely mimics the functions of natural heart tissue through the use of human-based materials.
A groundbreaking drug that helps regulate bone development has boosted growth rates in children with achondroplasia - the most common type of dwarfism - in a global trial led by Melbourne's Murdoch Children's Research Institute.
The clinical trial was random, regulated, double-blinded and broad-based. The drug was tested on 457 patients, aged 16-45, who had been diagnosed with Type 1 diabetes a short time before joining the trial. The trial took place in around 40 medical centers in Europe, Israel and South Africa. The patients in the trial were randomly assigned to one of two groups: One received the trial drug (DiaPep277-) through a subcutaneous injection once every three months, for a period of two years, while the control group was given a placebo in the same way.
To inform policy and identify best practices in helping high school students with disabilities successfully go to college and get good jobs, Cornell's School of Industrial and Labor Relations' (ILR) Employment and Disability Institute (EDI) will partner with New York state on a five-year, $5.1 million research study.
› Verified 1 days ago
| Provider Name | Jenna Cedillo |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1477007177 PECOS PAC ID: 8123307907 Enrollment ID: I20161118000401 |
News Archive
Two U.N. reports released on Wednesday examine the conditions faced by women around the world, the New York Times reports (MacFarquhar, 10/20). The World's Women 2010: Trends and Statistics report, which is published every five years, offers a compilation of "the latest data documenting progress for women worldwide in eight key areas: population and families, health, education, work, power and decision-making, violence against women, environment and poverty," according to a U.N. Statistics Division press release.
A team of bioengineers at Brigham and Women's Hospital is the first to report creating artificial heart tissue that closely mimics the functions of natural heart tissue through the use of human-based materials.
A groundbreaking drug that helps regulate bone development has boosted growth rates in children with achondroplasia - the most common type of dwarfism - in a global trial led by Melbourne's Murdoch Children's Research Institute.
The clinical trial was random, regulated, double-blinded and broad-based. The drug was tested on 457 patients, aged 16-45, who had been diagnosed with Type 1 diabetes a short time before joining the trial. The trial took place in around 40 medical centers in Europe, Israel and South Africa. The patients in the trial were randomly assigned to one of two groups: One received the trial drug (DiaPep277-) through a subcutaneous injection once every three months, for a period of two years, while the control group was given a placebo in the same way.
To inform policy and identify best practices in helping high school students with disabilities successfully go to college and get good jobs, Cornell's School of Industrial and Labor Relations' (ILR) Employment and Disability Institute (EDI) will partner with New York state on a five-year, $5.1 million research study.
› Verified 1 days ago
| Provider Name | Catherine Elizabeth Kristynik |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1467973222 PECOS PAC ID: 3274805437 Enrollment ID: I20170823000412 |
News Archive
Two U.N. reports released on Wednesday examine the conditions faced by women around the world, the New York Times reports (MacFarquhar, 10/20). The World's Women 2010: Trends and Statistics report, which is published every five years, offers a compilation of "the latest data documenting progress for women worldwide in eight key areas: population and families, health, education, work, power and decision-making, violence against women, environment and poverty," according to a U.N. Statistics Division press release.
A team of bioengineers at Brigham and Women's Hospital is the first to report creating artificial heart tissue that closely mimics the functions of natural heart tissue through the use of human-based materials.
A groundbreaking drug that helps regulate bone development has boosted growth rates in children with achondroplasia - the most common type of dwarfism - in a global trial led by Melbourne's Murdoch Children's Research Institute.
The clinical trial was random, regulated, double-blinded and broad-based. The drug was tested on 457 patients, aged 16-45, who had been diagnosed with Type 1 diabetes a short time before joining the trial. The trial took place in around 40 medical centers in Europe, Israel and South Africa. The patients in the trial were randomly assigned to one of two groups: One received the trial drug (DiaPep277-) through a subcutaneous injection once every three months, for a period of two years, while the control group was given a placebo in the same way.
To inform policy and identify best practices in helping high school students with disabilities successfully go to college and get good jobs, Cornell's School of Industrial and Labor Relations' (ILR) Employment and Disability Institute (EDI) will partner with New York state on a five-year, $5.1 million research study.
› Verified 1 days ago
| Provider Name | Jenna Wayne |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1598250755 PECOS PAC ID: 0547513772 Enrollment ID: I20181105002108 |
News Archive
Two U.N. reports released on Wednesday examine the conditions faced by women around the world, the New York Times reports (MacFarquhar, 10/20). The World's Women 2010: Trends and Statistics report, which is published every five years, offers a compilation of "the latest data documenting progress for women worldwide in eight key areas: population and families, health, education, work, power and decision-making, violence against women, environment and poverty," according to a U.N. Statistics Division press release.
A team of bioengineers at Brigham and Women's Hospital is the first to report creating artificial heart tissue that closely mimics the functions of natural heart tissue through the use of human-based materials.
A groundbreaking drug that helps regulate bone development has boosted growth rates in children with achondroplasia - the most common type of dwarfism - in a global trial led by Melbourne's Murdoch Children's Research Institute.
The clinical trial was random, regulated, double-blinded and broad-based. The drug was tested on 457 patients, aged 16-45, who had been diagnosed with Type 1 diabetes a short time before joining the trial. The trial took place in around 40 medical centers in Europe, Israel and South Africa. The patients in the trial were randomly assigned to one of two groups: One received the trial drug (DiaPep277-) through a subcutaneous injection once every three months, for a period of two years, while the control group was given a placebo in the same way.
To inform policy and identify best practices in helping high school students with disabilities successfully go to college and get good jobs, Cornell's School of Industrial and Labor Relations' (ILR) Employment and Disability Institute (EDI) will partner with New York state on a five-year, $5.1 million research study.
› Verified 1 days ago
| Provider Name | Aaron Gee Wong |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1073008694 PECOS PAC ID: 2466706619 Enrollment ID: I20181107001133 |
News Archive
Two U.N. reports released on Wednesday examine the conditions faced by women around the world, the New York Times reports (MacFarquhar, 10/20). The World's Women 2010: Trends and Statistics report, which is published every five years, offers a compilation of "the latest data documenting progress for women worldwide in eight key areas: population and families, health, education, work, power and decision-making, violence against women, environment and poverty," according to a U.N. Statistics Division press release.
A team of bioengineers at Brigham and Women's Hospital is the first to report creating artificial heart tissue that closely mimics the functions of natural heart tissue through the use of human-based materials.
A groundbreaking drug that helps regulate bone development has boosted growth rates in children with achondroplasia - the most common type of dwarfism - in a global trial led by Melbourne's Murdoch Children's Research Institute.
The clinical trial was random, regulated, double-blinded and broad-based. The drug was tested on 457 patients, aged 16-45, who had been diagnosed with Type 1 diabetes a short time before joining the trial. The trial took place in around 40 medical centers in Europe, Israel and South Africa. The patients in the trial were randomly assigned to one of two groups: One received the trial drug (DiaPep277-) through a subcutaneous injection once every three months, for a period of two years, while the control group was given a placebo in the same way.
To inform policy and identify best practices in helping high school students with disabilities successfully go to college and get good jobs, Cornell's School of Industrial and Labor Relations' (ILR) Employment and Disability Institute (EDI) will partner with New York state on a five-year, $5.1 million research study.
› Verified 1 days ago
| Provider Name | Leah Theresa Dantin |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1851742019 PECOS PAC ID: 8820325327 Enrollment ID: I20190806003685 |
News Archive
Two U.N. reports released on Wednesday examine the conditions faced by women around the world, the New York Times reports (MacFarquhar, 10/20). The World's Women 2010: Trends and Statistics report, which is published every five years, offers a compilation of "the latest data documenting progress for women worldwide in eight key areas: population and families, health, education, work, power and decision-making, violence against women, environment and poverty," according to a U.N. Statistics Division press release.
A team of bioengineers at Brigham and Women's Hospital is the first to report creating artificial heart tissue that closely mimics the functions of natural heart tissue through the use of human-based materials.
A groundbreaking drug that helps regulate bone development has boosted growth rates in children with achondroplasia - the most common type of dwarfism - in a global trial led by Melbourne's Murdoch Children's Research Institute.
The clinical trial was random, regulated, double-blinded and broad-based. The drug was tested on 457 patients, aged 16-45, who had been diagnosed with Type 1 diabetes a short time before joining the trial. The trial took place in around 40 medical centers in Europe, Israel and South Africa. The patients in the trial were randomly assigned to one of two groups: One received the trial drug (DiaPep277-) through a subcutaneous injection once every three months, for a period of two years, while the control group was given a placebo in the same way.
To inform policy and identify best practices in helping high school students with disabilities successfully go to college and get good jobs, Cornell's School of Industrial and Labor Relations' (ILR) Employment and Disability Institute (EDI) will partner with New York state on a five-year, $5.1 million research study.
› Verified 1 days ago
| Provider Name | Sarah San-wai Hung |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1992367171 PECOS PAC ID: 1254668759 Enrollment ID: I20190806003764 |
News Archive
Two U.N. reports released on Wednesday examine the conditions faced by women around the world, the New York Times reports (MacFarquhar, 10/20). The World's Women 2010: Trends and Statistics report, which is published every five years, offers a compilation of "the latest data documenting progress for women worldwide in eight key areas: population and families, health, education, work, power and decision-making, violence against women, environment and poverty," according to a U.N. Statistics Division press release.
A team of bioengineers at Brigham and Women's Hospital is the first to report creating artificial heart tissue that closely mimics the functions of natural heart tissue through the use of human-based materials.
A groundbreaking drug that helps regulate bone development has boosted growth rates in children with achondroplasia - the most common type of dwarfism - in a global trial led by Melbourne's Murdoch Children's Research Institute.
The clinical trial was random, regulated, double-blinded and broad-based. The drug was tested on 457 patients, aged 16-45, who had been diagnosed with Type 1 diabetes a short time before joining the trial. The trial took place in around 40 medical centers in Europe, Israel and South Africa. The patients in the trial were randomly assigned to one of two groups: One received the trial drug (DiaPep277-) through a subcutaneous injection once every three months, for a period of two years, while the control group was given a placebo in the same way.
To inform policy and identify best practices in helping high school students with disabilities successfully go to college and get good jobs, Cornell's School of Industrial and Labor Relations' (ILR) Employment and Disability Institute (EDI) will partner with New York state on a five-year, $5.1 million research study.
› Verified 1 days ago
| Provider Name | Angela Ann Dantin |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1942651104 PECOS PAC ID: 3375871494 Enrollment ID: I20190827001873 |
News Archive
Two U.N. reports released on Wednesday examine the conditions faced by women around the world, the New York Times reports (MacFarquhar, 10/20). The World's Women 2010: Trends and Statistics report, which is published every five years, offers a compilation of "the latest data documenting progress for women worldwide in eight key areas: population and families, health, education, work, power and decision-making, violence against women, environment and poverty," according to a U.N. Statistics Division press release.
A team of bioengineers at Brigham and Women's Hospital is the first to report creating artificial heart tissue that closely mimics the functions of natural heart tissue through the use of human-based materials.
A groundbreaking drug that helps regulate bone development has boosted growth rates in children with achondroplasia - the most common type of dwarfism - in a global trial led by Melbourne's Murdoch Children's Research Institute.
The clinical trial was random, regulated, double-blinded and broad-based. The drug was tested on 457 patients, aged 16-45, who had been diagnosed with Type 1 diabetes a short time before joining the trial. The trial took place in around 40 medical centers in Europe, Israel and South Africa. The patients in the trial were randomly assigned to one of two groups: One received the trial drug (DiaPep277-) through a subcutaneous injection once every three months, for a period of two years, while the control group was given a placebo in the same way.
To inform policy and identify best practices in helping high school students with disabilities successfully go to college and get good jobs, Cornell's School of Industrial and Labor Relations' (ILR) Employment and Disability Institute (EDI) will partner with New York state on a five-year, $5.1 million research study.
› Verified 1 days ago
| Provider Name | Nancy Nghe |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1609259027 PECOS PAC ID: 6507171774 Enrollment ID: I20200129000534 |
News Archive
Two U.N. reports released on Wednesday examine the conditions faced by women around the world, the New York Times reports (MacFarquhar, 10/20). The World's Women 2010: Trends and Statistics report, which is published every five years, offers a compilation of "the latest data documenting progress for women worldwide in eight key areas: population and families, health, education, work, power and decision-making, violence against women, environment and poverty," according to a U.N. Statistics Division press release.
A team of bioengineers at Brigham and Women's Hospital is the first to report creating artificial heart tissue that closely mimics the functions of natural heart tissue through the use of human-based materials.
A groundbreaking drug that helps regulate bone development has boosted growth rates in children with achondroplasia - the most common type of dwarfism - in a global trial led by Melbourne's Murdoch Children's Research Institute.
The clinical trial was random, regulated, double-blinded and broad-based. The drug was tested on 457 patients, aged 16-45, who had been diagnosed with Type 1 diabetes a short time before joining the trial. The trial took place in around 40 medical centers in Europe, Israel and South Africa. The patients in the trial were randomly assigned to one of two groups: One received the trial drug (DiaPep277-) through a subcutaneous injection once every three months, for a period of two years, while the control group was given a placebo in the same way.
To inform policy and identify best practices in helping high school students with disabilities successfully go to college and get good jobs, Cornell's School of Industrial and Labor Relations' (ILR) Employment and Disability Institute (EDI) will partner with New York state on a five-year, $5.1 million research study.
› Verified 1 days ago
| Provider Name | Thuyuyen Ngoc Hoang |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1447859913 PECOS PAC ID: 2567874407 Enrollment ID: I20201217000122 |
News Archive
Two U.N. reports released on Wednesday examine the conditions faced by women around the world, the New York Times reports (MacFarquhar, 10/20). The World's Women 2010: Trends and Statistics report, which is published every five years, offers a compilation of "the latest data documenting progress for women worldwide in eight key areas: population and families, health, education, work, power and decision-making, violence against women, environment and poverty," according to a U.N. Statistics Division press release.
A team of bioengineers at Brigham and Women's Hospital is the first to report creating artificial heart tissue that closely mimics the functions of natural heart tissue through the use of human-based materials.
A groundbreaking drug that helps regulate bone development has boosted growth rates in children with achondroplasia - the most common type of dwarfism - in a global trial led by Melbourne's Murdoch Children's Research Institute.
The clinical trial was random, regulated, double-blinded and broad-based. The drug was tested on 457 patients, aged 16-45, who had been diagnosed with Type 1 diabetes a short time before joining the trial. The trial took place in around 40 medical centers in Europe, Israel and South Africa. The patients in the trial were randomly assigned to one of two groups: One received the trial drug (DiaPep277-) through a subcutaneous injection once every three months, for a period of two years, while the control group was given a placebo in the same way.
To inform policy and identify best practices in helping high school students with disabilities successfully go to college and get good jobs, Cornell's School of Industrial and Labor Relations' (ILR) Employment and Disability Institute (EDI) will partner with New York state on a five-year, $5.1 million research study.
› Verified 1 days ago
| Provider Name | Joann Sarah Thomas |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1841899473 PECOS PAC ID: 7618389404 Enrollment ID: I20201221000974 |
News Archive
Two U.N. reports released on Wednesday examine the conditions faced by women around the world, the New York Times reports (MacFarquhar, 10/20). The World's Women 2010: Trends and Statistics report, which is published every five years, offers a compilation of "the latest data documenting progress for women worldwide in eight key areas: population and families, health, education, work, power and decision-making, violence against women, environment and poverty," according to a U.N. Statistics Division press release.
A team of bioengineers at Brigham and Women's Hospital is the first to report creating artificial heart tissue that closely mimics the functions of natural heart tissue through the use of human-based materials.
A groundbreaking drug that helps regulate bone development has boosted growth rates in children with achondroplasia - the most common type of dwarfism - in a global trial led by Melbourne's Murdoch Children's Research Institute.
The clinical trial was random, regulated, double-blinded and broad-based. The drug was tested on 457 patients, aged 16-45, who had been diagnosed with Type 1 diabetes a short time before joining the trial. The trial took place in around 40 medical centers in Europe, Israel and South Africa. The patients in the trial were randomly assigned to one of two groups: One received the trial drug (DiaPep277-) through a subcutaneous injection once every three months, for a period of two years, while the control group was given a placebo in the same way.
To inform policy and identify best practices in helping high school students with disabilities successfully go to college and get good jobs, Cornell's School of Industrial and Labor Relations' (ILR) Employment and Disability Institute (EDI) will partner with New York state on a five-year, $5.1 million research study.
› Verified 1 days ago
| Provider Name | Mimi Duong |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1295306272 PECOS PAC ID: 4082008149 Enrollment ID: I20220307001109 |
News Archive
Two U.N. reports released on Wednesday examine the conditions faced by women around the world, the New York Times reports (MacFarquhar, 10/20). The World's Women 2010: Trends and Statistics report, which is published every five years, offers a compilation of "the latest data documenting progress for women worldwide in eight key areas: population and families, health, education, work, power and decision-making, violence against women, environment and poverty," according to a U.N. Statistics Division press release.
A team of bioengineers at Brigham and Women's Hospital is the first to report creating artificial heart tissue that closely mimics the functions of natural heart tissue through the use of human-based materials.
A groundbreaking drug that helps regulate bone development has boosted growth rates in children with achondroplasia - the most common type of dwarfism - in a global trial led by Melbourne's Murdoch Children's Research Institute.
The clinical trial was random, regulated, double-blinded and broad-based. The drug was tested on 457 patients, aged 16-45, who had been diagnosed with Type 1 diabetes a short time before joining the trial. The trial took place in around 40 medical centers in Europe, Israel and South Africa. The patients in the trial were randomly assigned to one of two groups: One received the trial drug (DiaPep277-) through a subcutaneous injection once every three months, for a period of two years, while the control group was given a placebo in the same way.
To inform policy and identify best practices in helping high school students with disabilities successfully go to college and get good jobs, Cornell's School of Industrial and Labor Relations' (ILR) Employment and Disability Institute (EDI) will partner with New York state on a five-year, $5.1 million research study.
› Verified 1 days ago
| Provider Name | Parnaz Adibian |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1831776046 PECOS PAC ID: 6608260781 Enrollment ID: I20220307001890 |
News Archive
Two U.N. reports released on Wednesday examine the conditions faced by women around the world, the New York Times reports (MacFarquhar, 10/20). The World's Women 2010: Trends and Statistics report, which is published every five years, offers a compilation of "the latest data documenting progress for women worldwide in eight key areas: population and families, health, education, work, power and decision-making, violence against women, environment and poverty," according to a U.N. Statistics Division press release.
A team of bioengineers at Brigham and Women's Hospital is the first to report creating artificial heart tissue that closely mimics the functions of natural heart tissue through the use of human-based materials.
A groundbreaking drug that helps regulate bone development has boosted growth rates in children with achondroplasia - the most common type of dwarfism - in a global trial led by Melbourne's Murdoch Children's Research Institute.
The clinical trial was random, regulated, double-blinded and broad-based. The drug was tested on 457 patients, aged 16-45, who had been diagnosed with Type 1 diabetes a short time before joining the trial. The trial took place in around 40 medical centers in Europe, Israel and South Africa. The patients in the trial were randomly assigned to one of two groups: One received the trial drug (DiaPep277-) through a subcutaneous injection once every three months, for a period of two years, while the control group was given a placebo in the same way.
To inform policy and identify best practices in helping high school students with disabilities successfully go to college and get good jobs, Cornell's School of Industrial and Labor Relations' (ILR) Employment and Disability Institute (EDI) will partner with New York state on a five-year, $5.1 million research study.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Eye Trends 406 Sawdust Rd, The Woodlands, TX 77380-2243 Ph: (281) 465-9505 | Eye Trends 6625 Spring Stuebner Rd Ste 215, Spring, TX 77389-5356 Ph: (281) 350-2020 |
News Archive
Two U.N. reports released on Wednesday examine the conditions faced by women around the world, the New York Times reports (MacFarquhar, 10/20). The World's Women 2010: Trends and Statistics report, which is published every five years, offers a compilation of "the latest data documenting progress for women worldwide in eight key areas: population and families, health, education, work, power and decision-making, violence against women, environment and poverty," according to a U.N. Statistics Division press release.
A team of bioengineers at Brigham and Women's Hospital is the first to report creating artificial heart tissue that closely mimics the functions of natural heart tissue through the use of human-based materials.
A groundbreaking drug that helps regulate bone development has boosted growth rates in children with achondroplasia - the most common type of dwarfism - in a global trial led by Melbourne's Murdoch Children's Research Institute.
The clinical trial was random, regulated, double-blinded and broad-based. The drug was tested on 457 patients, aged 16-45, who had been diagnosed with Type 1 diabetes a short time before joining the trial. The trial took place in around 40 medical centers in Europe, Israel and South Africa. The patients in the trial were randomly assigned to one of two groups: One received the trial drug (DiaPep277-) through a subcutaneous injection once every three months, for a period of two years, while the control group was given a placebo in the same way.
To inform policy and identify best practices in helping high school students with disabilities successfully go to college and get good jobs, Cornell's School of Industrial and Labor Relations' (ILR) Employment and Disability Institute (EDI) will partner with New York state on a five-year, $5.1 million research study.
› Verified 1 days ago
Eye Trends Optometrist Medicare: Medicare Enrolled Practice Location: 4710 Louetta Rd, Spring, TX 77388 Phone: 281-350-2020 | |
My Eyelab Optometrist Medicare: Not Enrolled in Medicare Practice Location: 20115 Stuebner Airline Rd, Spring, TX 77379 Phone: 561-275-2020 | |
Luis Gerardo Diaz, OD Optometrist Medicare: Medicare Enrolled Practice Location: 25511 Budde Rd Ste 3801, Spring, TX 77380 Phone: 281-419-3355 | |
Eyetrends-parkway Optometrist Medicare: Not Enrolled in Medicare Practice Location: 6625 Spring Stuebner Rd Ste 215, Spring, TX 77389 Phone: 281-408-2020 | |
Dr. Aimee Beth Lee, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 6526 Louetta Rd Ste C, Spring, TX 77379 Phone: 281-376-4551 Fax: 281-251-8684 | |
Kiannah Nicole Lagunas, OD Optometrist Medicare: Medicare Enrolled Practice Location: 10227 Birchline Dr, Spring, TX 77379 Phone: 281-639-5665 |